Bioventix plc

("Bioventix" or the "Company")

Board Appointment

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics is delighted to announce that it has appointed Joanne (Jo) Pisani to the Board, as an independent Non-Executive Director, with immediate effect. Jo will chair the Company's Audit Committee.

Jo is a chartered engineer with a distinguished background in the Pharmaceutical, Life Sciences and Biotech sectors. She has held roles at GSK and BP in strategy, commercial and operational functions before working in strategic consultancy. She led PwC's UK Pharmaceutical and Life Sciences practice, assisting clients with developing strategy, designing and implementing transformational change and completing M&A transactions.

Jo is a passionate supporter of critical public health issues, such as tackling dementia, rare diseases and anti-microbial resistance. She focuses on supporting charities, universities and business start-ups. She is chair of Birmingham's Precision Health Technology Accelerator and also chairs the Advisory Board for London's MedCity. She serves on the boards of the UK Dementia Research Institute, LifeArc, The RSA Group, London and Partners and Beacon.  She is also a Non-Executive Director and strategic advisor to biotech companies in the UK, Finland and Spain  

Ian Nicholson, Chairman, commented: "The Board is delighted to welcome Jo to Bioventix. She brings considerable leadership and strategic experience in Life Sciences and biotech businesses, large and small, that is highly relevant to Bioventix and the opportunities being addressed by the Company. I am confident that she will add considerable value to the Company."

For further information please contact:

Regulatory disclosures

INFORMATION REQUIRED UNDER RULE 17 AND SCHEDULE 2, PARAGRAPH (G) OF THE AIM RULES FOR COMPANIES ("AIM RULES")

There is no further information to be disclosed in relation to the director appointment pursuant to Rule 17 and Schedule 2, paragraph (g) of the AIM Rules.